Covid 19 Research using Clinical Trials (Home Page)
Report for D001284: Atrophy NIH
(Synonyms: Atrophy)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
There is one clinical trial.
Clinical Trials
1 Effects of Three Months of COVID-19 Lockdown Induced Deconditioning After 13 Months of High Intensity Exercise Training in Early Postmenopausal Women
While "conditioning" by exercise training has been widely evaluated, the available literature on "passive deconditioning" (i.e. forced deconditioning) is predominately limited to studies with or with almost complete mechanical and/or metabolic immobilization/sedation of the respective functional system (e.g. paralysis, bedriddenness). Vice versa, the effects of moderately long interruptions of dedicated types of exercise while maintaining everyday activity are rarely addressed. However, this topic is of high relevance, e.g. considering that breaks of health-related exercise programs due to increased family/occupational stress, vacation or temporary orthopedic limitation are rather frequent in everyday life. In the present project we aimed to determine the effects of 3 months of physical deconditioning due to COVID-19 induced lockdown after 13 month of high intensity endurance and resistance exercise in early postmenopausal women on parameters related to health and physical fitness.
NCT04420806 Exercise Detraining Muscle Weakness Muscle Atrophy Other: HIT-exercise Other: Sham intervention MeSH:Muscle Weakness Muscular Atrophy Atrophy
HPO:Skeletal muscle atrophy
Primary Outcomes
Description: Body composition as determined by Dual-Energy x-Ray Absorptiometry
Measure: Body composition Time: From intervention end to 3 months FU
Secondary Outcomes
Description: Hip-/Leg extension strength as determined by an isokinetic leg press
Measure: Hip-/Leg extension strength Time: From intervention end to 3 months FU
Description: cardio-metabolic risk factors summarized in the Metabolic Syndrome Z-Score according to the definition of the International Diabetes Federation
Measure: Metabolic Syndrome Time: From intervention end to 3 months FU
Description: BMD at the lumbar spine and total hip as determined by Dual Energy x-Ray Absorptiometry
Measure: Bone Mineral Density (BMD) Time: From intervention end to 3 months FU
Description: Menopausal symptoms as determined by the "Menopausal Rating Scale" (MRS) with a scale from 0 (no complaints) to 4 (very serious complaints).
Measure: Menopausal symptoms Time: From intervention end to 3 months FU
Description: Back and joint pain as determined by a standardized pain questionnaire with a scale from 0 (never) to 7 (permanent) for pain frequency or 0 (no pain) to 7 (extremely) for pain severity.
Measure: Back and joint pain Time: From intervention end to 3 months FU
HPO Nodes
Primary Outcomes
Description: Body composition as determined by Dual-Energy x-Ray Absorptiometry
Measure: Body composition Time: From intervention end to 3 months FUSecondary Outcomes
Description: Hip-/Leg extension strength as determined by an isokinetic leg press
Measure: Hip-/Leg extension strength Time: From intervention end to 3 months FUDescription: cardio-metabolic risk factors summarized in the Metabolic Syndrome Z-Score according to the definition of the International Diabetes Federation
Measure: Metabolic Syndrome Time: From intervention end to 3 months FUDescription: BMD at the lumbar spine and total hip as determined by Dual Energy x-Ray Absorptiometry
Measure: Bone Mineral Density (BMD) Time: From intervention end to 3 months FUDescription: Menopausal symptoms as determined by the "Menopausal Rating Scale" (MRS) with a scale from 0 (no complaints) to 4 (very serious complaints).
Measure: Menopausal symptoms Time: From intervention end to 3 months FUDescription: Back and joint pain as determined by a standardized pain questionnaire with a scale from 0 (never) to 7 (permanent) for pain frequency or 0 (no pain) to 7 (extremely) for pain severity.
Measure: Back and joint pain Time: From intervention end to 3 months FU